Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
RATIONALE: Despite relative antigenic stability, respiratory syncytial virus (RSV) reinfects throughout life. After more than 40 years of research, no effective human vaccine exists and correlates of protection remain poorly defined. Most current vaccine candidates seek to induce high levels of RSV-specific serum neutralizing antibodies, which are associated with reduced RSV-related hospitalization rates in observational studies but may not actually prevent infection. OBJECTIVES: To characterize correlates of protection from infection and the generation of RSV-specific humoral memory to promote effective vaccine development. METHODS: We inoculated 61 healthy adults with live RSV and studied protection from infection by serum and mucosal antibody. We analyzed RSV-specific peripheral blood plasmablast and memory B-cell frequencies and antibody longevity. MEASUREMENTS AND MAIN RESULTS: Despite moderately high levels of preexisting serum antibody, 34 (56%) became infected, of whom 23 (68%) developed symptomatic colds. Prior RSV-specific nasal IgA correlated significantly more strongly with protection from polymerase chain reaction-confirmed infection than serum neutralizing antibody. Increases in virus-specific antibody titers were variable and transient in infected subjects but correlated with plasmablasts that peaked around Day 10. During convalescence, only IgG (and no IgA) RSV-specific memory B cells were detectable in peripheral blood. This contrasted with natural influenza infection, in which virus-specific IgA memory B cells were readily recovered. CONCLUSIONS: This observed specific defect in IgA memory may partly explain the ability of RSV to cause recurrent symptomatic infections. If so, vaccines able to induce durable RSV-specific IgA responses may be more protective than those generating systemic antibody alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773 · cited 1×
“Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization worldwide, infecting around 34 million children each year (1).”
Follicular Helper CD4 T Cells (T FH )
Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C., & Walsh, E. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043951 · Cited by 2,226
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Ritz, C., & Streibig, J. C. (2005) · Journal of Statistical Software · doi:10.18637/jss.v012.i05 · Cited by 1,438
Duration of Humoral Immunity to Common Viral and Vaccine Antigens
Amanna, I. J., Carlson, N. E., & Slifka, M. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066092 · Cited by 1,286 · cited 1×
“To assess whether preinfection RSV-specific MBCs correlate with protection we analyzed RSV-specific MBC frequencies and compared with those against measles virus, a related pathogen to which protection following natural infection or live-attenuated vaccination is known to be long-lasting (34).”
ResultHumoral Immunity Due to Long-Lived Plasma Cells
Slifka, M. K., Antia, R., Whitmire, J. K., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80541-5 · Cited by 1,245
Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution
Rennard, S. I., Basset, G., Lecossier, D., O'Donnell, K. M., Pinkston, P., Martin, P. G., & Crystal, R. G. (1986) · Journal of Applied Physiology · doi:10.1152/jappl.1986.60.2.532 · Cited by 1,131
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., et al. (2008) · Nature · doi:10.1038/nature06890 · Cited by 1,025
Self-citation
Cited by
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Griffiths, C., Drews, S. J., & Marchant, D. J. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-16 · Cited by 586
Immunosenescence and human vaccine immune responses
Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0164-9 · Cited by 530
Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P. J., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 457
Self-citationRespiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Mazur, N. I., Terstappen, J., Baral, R., Bardají, A., Beutels, P., Buchholz, U. J., Cohen, C., Crowe, J. E., Cutland, C. L., Eckert, L., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00291-2 · Cited by 420
The Human Immune Response to Respiratory Syncytial Virus Infection
Russell, C. D., Unger, S. A., Walton, M., & Schwarze, J. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00090-16 · Cited by 403
The CD8 T Cell Response to Respiratory Virus Infections
Schmidt, M. E., & Varga, S. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00678 · Cited by 371
“Indeed, despite a correlation between pre-existing nasal IgA and protection from reinfection, the development of long-lasting RSV- and RV-specific mucosal IgA responses was poor in infected adults (22, 23).”
BackgroundRespiratory syncytial virus infection in adults
Nam, H. H., & Ison, M. G. (2019) · BMJ · doi:10.1136/bmj.l5021 · Cited by 332
A proof of concept for structure-based vaccine design targeting RSV in humans
Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., Holman, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2019) · Science · doi:10.1126/science.aav9033 · Cited by 333
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317
Jozwik, A., Habibi, M. S., Paras, A., Zhu, J., Guvenel, A., Dhariwal, J., Almond, M., Wong, E. H. C., Sykes, A., Maybeno, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms10224 · Cited by 297
Self-citationCrawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
Immunological Lessons from Respiratory Syncytial Virus Vaccine Development
Ruckwardt, T. J., Morabito, K. M., & Graham, B. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.007 · Cited by 185
Experimental infection of human volunteers
Roestenberg, M., Hoogerwerf, M.-A., Ferreira, D. M., Mordmüller, B., & Yazdanbakhsh, M. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30177-4 · Cited by 170
Updates on immunologic correlates of vaccine-induced protection
Plotkin, S. A. (2020) · Vaccine · doi:10.1016/j.vaccine.2019.10.046 · Cited by 165
Age-associated alterations in immune function and inflammation
Lewis, E. D., Wu, D., & Meydani, S. N. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110576 · Cited by 111
Local heroes or villains: tissue-resident memory T cells in human health and disease
Sasson, S. C., Gordon, C. L., Christo, S. N., Klenerman, P., & Mackay, L. K. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0359-1 · Cited by 111
“Respiratory syncytial virus Respiratory syncytial virus (RSV) is an acute respiratory infection,(89,90) and unlike influenza, natural RSV infection does not elicit complete strain-specific protection upon re-exposure.(91) It has been reported that RSV-specific CD8 T cells are enriched within the lung compared to the b…”
BackgroundAntibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns
Baumgarth, N., Nikolich-Žugich, J., Lee, F. E.-H., & Bhattacharya, D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000839 · Cited by 84
Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey, I., & Saelens, X. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1675520 · Cited by 32
“immunization, as elevated anti-RSV IgA levels in the respiratory tract are highly associated with protection against RSV [41].”
Background
Metadata
- Authors
- Habibi, M. S., Jozwik, A., Makris, S., Dunning, J., Paras, A., DeVincenzo, J. P., de Haan, C. A. M., Wrammert, J., Openshaw, P. J. M., & Chiu, C.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-01
- Volume
- 191
- Issue
- 9
- Pages
- 1040-1049
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2130386320
- Cited by
- 287
- References
- 49
- FWCI
- 14.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.